ArticleInternational journal of hematology2026
Clinical impact of infused CD3-positive cell dose in unrelated peripheral blood stem cell transplantation.
Article in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The clinical impact of the infused CD3-positive cell dose on outcomes after unrelated peripheral blood stem cell transplantation (uPBSCT) remains uncertain, particularly regarding graft-versus-host disease (GVHD). We retrospectively analyzed 75 patients who underwent first uPBSCT between 2016 and 2024, dichotomized at the median infused CD3-positive cell dose (20 × 10⁷ cells/kg). The cumulative incidence of grade II-IV acute GVHD was significantly higher in the high CD3 group (45.7% vs 20.0% at day-100, p = 0.02). In multivariable analysis, high CD3-positive cell dose independently predicted acute GVHD (HR 3.15, 95% confidence interval 1.26-7.86) but was not associated with overall survival, non-relapse mortality, relapse, or chronic GVHD. Target-organ involvement and severity were similar between groups, although grade II acute GVHD was more frequent in the high CD3 group. In an exploratory analysis of patients receiving systemic corticosteroids for grade II-IV acute GVHD, progression of acute GVHD after first-line treatment occurred only in the high CD3 group, though based on small numbers and not statistically significant (p = 0.09). No GVHD-related mortality occurred. A higher infused CD3-positive cell dose increases acute GVHD risk without affecting other transplant outcomes and may serve as a practical marker of acute alloreactivity to guide risk-adapted GVHD prophylaxis.
Indexed as
Identifiers
42848168What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.